Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GridAI Technologies ( (GRDX) ) has issued an announcement.
GridAI Technologies Corp., formerly Entero Therapeutics, exited its ownership in ImmunogenX, LLC through a rescission of a prior merger, marking a significant disposition that materially reshapes its balance sheet and consolidates focus away from the ImmunogenX business. On December 31, 2025, the company, ImmunogenX, LLC and former ImmunogenX, Inc. shareholders completed a rescission transaction, originally agreed in March 2025 and amended in July 2025, under which GridAI transferred all of its membership interests in ImmunogenX, LLC back to the former shareholders, removing ImmunogenX as a subsidiary and reversing related assets, liabilities and equity interests from its books; the firm has provided unaudited pro forma consolidated financial statements to show the impact of this unwinding on its historical financials.
More about GridAI Technologies
Average Trading Volume: 140,725
Technical Sentiment Signal: Hold
Current Market Cap: $16.31M
For detailed information about GRDX stock, go to TipRanks’ Stock Analysis page.